Update on the management of prostate cancer with goserelin acetate: patient perspectives
Shandra WilsonDivision of Urology, University of Colorado, Aurora, CO, USAAbstract: The guidelines for the use of androgen deprivation therapy (ADT) have changed significantly over the last 5 years. This paper reviews the current recommendations and documents the reasons for these changes, in a revi...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2009-08-01
|
| Series: | Cancer Management and Research |
| Online Access: | http://www.dovepress.com/update-on-the-management-of-prostate-cancer-with-goserelin-acetate-pat-a3447 |
| _version_ | 1828421015912316928 |
|---|---|
| author | Shandra Wilson |
| author_facet | Shandra Wilson |
| author_sort | Shandra Wilson |
| collection | DOAJ |
| description | Shandra WilsonDivision of Urology, University of Colorado, Aurora, CO, USAAbstract: The guidelines for the use of androgen deprivation therapy (ADT) have changed significantly over the last 5 years. This paper reviews the current recommendations and documents the reasons for these changes, in a review of the world’s literature on ADT over the last 5 years. Special emphasis on randomized controlled trials and high-impact journals was included in the Medline search and review. One hundred articles on this topic written in the last 5 years were reviewed. Fifty-nine contained nonindustry-biased findings in major-impact journals and were available in English. The benefits of ADT are evident in several areas, including neoadjuvantly and adjuvantly in patients treated with external beam radiation therapy for intermediate- and high-risk disease; in patients who have undergone prostatectomy and who are found to have lymph node involvement on surgical resection; in high-risk patients after definitive therapy; and in patients who have developed symptomatic local progression or metastasis. This paper reviews the risks and benefits in each of these scenarios and the risks of androgen deprivation in general, and delineates the areas where ADT was previously recommended, but has been found to no longer be of benefit.Keywords: prostate cancer, goserelin acetate |
| first_indexed | 2024-12-10T15:22:55Z |
| format | Article |
| id | doaj.art-d7871ad8ee7d48d8a70790f30167104b |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-10T15:22:55Z |
| publishDate | 2009-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-d7871ad8ee7d48d8a70790f30167104b2022-12-22T01:43:38ZengDove Medical PressCancer Management and Research1179-13222009-08-012009default99105Update on the management of prostate cancer with goserelin acetate: patient perspectivesShandra WilsonShandra WilsonDivision of Urology, University of Colorado, Aurora, CO, USAAbstract: The guidelines for the use of androgen deprivation therapy (ADT) have changed significantly over the last 5 years. This paper reviews the current recommendations and documents the reasons for these changes, in a review of the world’s literature on ADT over the last 5 years. Special emphasis on randomized controlled trials and high-impact journals was included in the Medline search and review. One hundred articles on this topic written in the last 5 years were reviewed. Fifty-nine contained nonindustry-biased findings in major-impact journals and were available in English. The benefits of ADT are evident in several areas, including neoadjuvantly and adjuvantly in patients treated with external beam radiation therapy for intermediate- and high-risk disease; in patients who have undergone prostatectomy and who are found to have lymph node involvement on surgical resection; in high-risk patients after definitive therapy; and in patients who have developed symptomatic local progression or metastasis. This paper reviews the risks and benefits in each of these scenarios and the risks of androgen deprivation in general, and delineates the areas where ADT was previously recommended, but has been found to no longer be of benefit.Keywords: prostate cancer, goserelin acetatehttp://www.dovepress.com/update-on-the-management-of-prostate-cancer-with-goserelin-acetate-pat-a3447 |
| spellingShingle | Shandra Wilson Update on the management of prostate cancer with goserelin acetate: patient perspectives Cancer Management and Research |
| title | Update on the management of prostate cancer with goserelin acetate: patient perspectives |
| title_full | Update on the management of prostate cancer with goserelin acetate: patient perspectives |
| title_fullStr | Update on the management of prostate cancer with goserelin acetate: patient perspectives |
| title_full_unstemmed | Update on the management of prostate cancer with goserelin acetate: patient perspectives |
| title_short | Update on the management of prostate cancer with goserelin acetate: patient perspectives |
| title_sort | update on the management of prostate cancer with goserelin acetate patient perspectives |
| url | http://www.dovepress.com/update-on-the-management-of-prostate-cancer-with-goserelin-acetate-pat-a3447 |
| work_keys_str_mv | AT shandrawilson updateonthemanagementofprostatecancerwithgoserelinacetatepatientperspectives |